GMV has teamed up with the Extremadura Health Service to develop the PoPS (Personalized Oriented Drug Prescription System) tool
Can digital technology applied to clinical practice assist healthcare professionals in prescribing individualized pharmacological treatments? This health and sustainability challenge involves determining whether a specific medication will be effective for a patient and, if so, at what dosage, using technological tools to support healthcare professionals and avoid side effects and adverse reactions. The Extremadura Health Service (SES) has addressed this challenge through its leadership on MedeA, a pioneering project in Spain, supported by the expertise and advanced algorithmic developments of technology multinational GMV. Specifically, GMV is actively participating in the collaborative project to create a personalized drug prescription support tool called PoPS.
MedeA is an ambitious project developed in Extremadura, as a representative subgroup of the European population, and functioning as a pilot test due to the unique characteristics of this autonomous region (a single, homogeneous healthcare system and a small population). The goal is for the project to be validated and, as Dr. Llerena has said, to subsequently expand. His personal commitment to making this project a reality is particularly commendable: the research work spans thirty years and has been laying the groundwork for the MedeA project since 2013.
The goal of MedeA is to develop technological systems that support clinical decision-making, including a Personalized Oriented Drug Prescription System. This initiative is disruptive for three reasons: 1) its funding approach through public-private collaboration in innovative public biosanitary procurement; 2) its focus on a single healthcare system such as the Extremadura Health Service (SES), where the project is conceived as a comprehensive, cross-cutting system for the entire population, minimizing healthcare and social inequities; 3) it empowers physicians with a digitally supported prescription tool, enabling personalized therapy decisions by considering genetic information within the patient's medical history when determining the optimal drug combination.